气候变化领域集成服务门户(CCPortal): Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact

CCPortal

DOI	10.1136/bmjopen-2023-077129
	Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact
	Laroche, Jason Keith; Alvarenga, Rodrigo; Collins, Michael; Costelloe, Thomas; De Soete, Wouter; Faludi, Jeremy; Rens, Kristel
发表日期	2024
ISSN	2044-6055
起始页码	14
结束页码	1
卷号	14 期号:1
英文摘要	Objective This study aims to calculate the global warming potential, in carbon dioxide (CO2) equivalent emissions, from all in-scope activities involved in a phase-1 clinical study.Design Retrospective analysis.Data source Internal data held by Janssen Pharmaceuticals.Studies included Janssen-sponsored TMC114FD1HTX1002 study conducted between 2019 and 2021.Main outcome Measure CO2 equivalents (CO2e) for in-scope clinical trial activities calculated according to intergovernmental panel on climate change 2021 impact assessment methodology.Results The CO2e emissions generated by the trial were 17.65 tonnes. This is equivalent to the emissions generated by driving an average petrol-fueled family car 71 004 km or roughly 1.8 times around the circumference of the Earth. Commuting to the clinical site by the study participants generated the most emissions (5419 kg, 31% of overall emissions), followed by trial site utilities (2725 kg, 16% of overall emissions) and site staff travel (2560 kg, 15% of overall emissions). In total, the movement of people (participant travel, site staff travel and trial site staff travel) accounted for 8914 kg or 51% of overall trial emissions.Conclusions Decentralised trial models which seek to bring clinical trial operations closer to the participant offer opportunities to reduce participant travel. The electrification of sponsor vehicle fleets and society's transition towards electric vehicles may result in further reductions.Trial registration number NCT04208061.
英文关键词	Clinical Trial; Clinical trials; Health policy
语种	英语
WOS研究方向	General & Internal Medicine
WOS类目	Medicine, General & Internal
WOS记录号	WOS:001156806400007
来源期刊	BMJ OPEN
文献类型	期刊论文
条目标识符	http://gcip.llas.ac.cn/handle/2XKMVOVA/296883
作者单位	Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Delft University of Technology; Johnson & Johnson; Janssen Pharmaceuticals
推荐引用方式 GB/T 7714	Laroche, Jason Keith,Alvarenga, Rodrigo,Collins, Michael,et al. Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact[J],2024,14(1).
APA	Laroche, Jason Keith.,Alvarenga, Rodrigo.,Collins, Michael.,Costelloe, Thomas.,De Soete, Wouter.,...&Rens, Kristel.(2024).Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact.BMJ OPEN,14(1).
MLA	Laroche, Jason Keith,et al."Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact".BMJ OPEN 14.1(2024).